Complete deletion of Ranitidine from the list of benefits

such as Curan & Albis

Discontinued due to maintenance of unclaimed medicines that are not produced or expired

The benefit was suspended as of September 26, 2019, due to the detection of NDMA

Most ranitidine products, which were suspended due to adulteration in September 2019, will be removed from the reimbursement list as of November.

 

This is because there has been no production performance over the past three years or no insurance benefit claims over the past two years.

 

There are only three Ranitidine products remaining on the November list.

 

According to the industry on the 30th, unclaimed medicines were deleted and unproduced, and expired medicines were deleted from the November benefit list, leading to the expulsion of the majority of ranitidine preparations.

 

Ranitidine preparations were suspended on September 26, 2019, after the impurity NDMA (N-nitrosodimethylamine) was detected.

 

Although it has been on the benefits list with benefits suspended, it has been completely removed from the list due to the recent overhaul of unclaimed and unproduced medicines.

 

In order to normalize the benefits, there is no choice but to apply for benefits again, but as it is analyzed that it will be difficult to maintain the license through renewal, it appears that it will virtually be permanently excluded from the market.

 

Unclaimed medicines are those that have not been claimed for insurance benefits over the past two years (July 1, 2021 - June 30, 2023) and are subject to deletion from the benefits list.

 

125 items were deleted from the November list.

 

Unproduced or expired medicines are medicines that have not been produced or imported for the past three years (January 1, 2020, to December 31, 2022) and are deleted from the benefit list if their expiration date or expiration date has expired.

 

This time, 961 items were deleted.

 

Ildong Pharmaceutical's Curan (5 products), which was the flagship product of a single ranitidine drug, was deleted due to non-production and expired expiration dates.

 

Daewoong Pharmaceutical's Albis Tablet, which had the highest performance among combination drugs, was also removed from the benefits list due to non-production and expiration date.

 

This time, 46 items identical to Alvis disappeared from the benefit list.

 

Now, there are only three ranitidine products remaining on the payroll list.

 

The combination drug is Anacid from Aju Pharmaceutical, and the single drug is Genupharma Latini Tablet and SCD Ranitidine 150mg.

 

The three items were also suspended as of September 26, 2019.